![Matter / Science / Lithium / Lithium pharmacology / Treatment of bipolar disorder / Drug discovery / Design of experiments / Clinical trial / Pharmaceutical drug / Chemistry / Pharmacology / Mood stabilizers Matter / Science / Lithium / Lithium pharmacology / Treatment of bipolar disorder / Drug discovery / Design of experiments / Clinical trial / Pharmaceutical drug / Chemistry / Pharmacology / Mood stabilizers](/pdf-icon.png)
| Document Date: 2011-07-25 18:53:25 Open Document File Size: 29,50 KBShare Result on Facebook
Company Medesis Pharma / / Continent North America / Europe / / Country France / / Event Analyst Recommendation / FDA Phase / / IndustryTerm treatment of Huntington’s disease / pharmaceutical product / drug delivery technology / treatment of bipolar disorder / metal ions / / MedicalCondition bipolar disorders / multiple sclerosis / diseases / disease / chronic long term treatment / neurodegenerative diseases / Huntington’s disease / bipolar disorder / / Organization Committee for Orphan Medicinal Products / / Person Jean-Claude Maurel / / Position representative / President and CEO / / Product Lithium citrate / HD / NP03 / / Technology drug delivery technology / / URL www.medesispharma.com / http /
SocialTag |